Research And Markets Research And Markets
0 CHECKOUT

Global Cancer Biomarkers Market 2015-2019

  • ID: 3069443
  • January 2015
  • Region: Global
  • 89 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Astellas Pharma US
  • Celldex Therapeutics
  • Exact Sciences
  • Morphotek
  • Polymedco
  • MORE

About Cancer Biomarkers
Biomarkers are molecules present in the blood, other body fluids such as serum, urine, or in tissue that are indicators of a disease or abnormal conditions. Biomarkers are mostly used as diagnostic tools. Biomarkers help in identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of the drug discovery process. Cancer Biomarkers are proteins or metabolites indicative of tumor state and progression characteristics. They are non-invasive, enable high speed cancer diagnosis and also enhance early cancer detection and screening. The best example of a cancer biomarker is that of prostate specific antigen. PSA is measured in the blood to screen for and monitor treatment for prostate cancer. PSA, as a biomarker helps the doctors to monitor the progress of the cancer. It also helps to evaluate the response of the cancer to the treatment therapy.

The analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.26 percent over the period 2014-2019.

Covered in this Report
The report, Global Cancer Biomarkers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in READ MORE >

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Astellas Pharma US
  • Celldex Therapeutics
  • Exact Sciences
  • Morphotek
  • Polymedco
  • MORE

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Incidence and Prevalence
08. Biomarkers Used in Cancer Diagnosis
08.1.1 Cancer Biomarkers : FDA Approved till 2012
08.1.2 Cancer Biomarkers : FDA Approved 2013
09. FDA Approval Process for Protein-Based Cancer Biomarkers
10. Geographical Segmentation
10.1 Cancer Biomarkers Market in the Americas
10.1.1 Market Size and Forecast
10.1.2 Cancer Biomarkers Market in US
10.2 Cancer Biomarkers Market in the EMEA Region
10.2.1 Market Size and Forecast
10.3 Cancer Biomarkers Market in APAC Region
10.3.1 Market Size and Forecast
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Vendor Analysis 2014
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Abbott Laboratories
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Business Strategy
19.1.5 Revenue by Business Segmentation
19.1.6 Revenue Comparison 2011 and 2012
19.1.7 Revenue by Geographical Segmentation
19.1.8 Key Information
19.1.9 SWOT Analysis
19.2 Affymetrix
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue 2013
19.2.5 Business Segmentation by Revenue 2012 and 2013
19.2.6 Sales by Geography
19.2.7 Business Strategy
19.2.8 Key Information
19.2.9 SWOT Analysis
19.3 Illumina
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation
19.3.4 Geographical Segmentation by Revenue 2013
19.3.5 Business Strategy
19.3.6 Key Information
19.3.7 SWOT Analysis
19.4 Qiagen
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Product Segmentation by Revenue 2013
19.4.4 Product Segmentation by Revenue 2012 and 2013
19.4.5 Geographical Segmentation by Revenue 2013
19.4.6 Business Strategy
19.4.7 Recent Developments
19.4.8 SWOT Analysis
19.5 Quest Diagnostics
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation by Revenue 2013
19.5.4 Business Segmentation by Revenue 2011-2013
19.5.5 Geographical Segmentation by Revenue 2013
19.5.6 Business Strategy
19.5.7 Recent Developments
19.5.8 SWOT Analysis
19.6 Roche Diagnostics
19.6.1 Key Facts
19.6.2 Business Overview
19.6.3 Business Segmentation by Revenue 2013
19.6.4 Geographical Segmentation by Revenue 2013
19.6.5 Business Strategy
19.6.6 Key Developments
19.6.7 SWOT Analysis
20. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Cancer Biomarkers Market 2014–2019 (US$ billion)
Exhibit 3: Incidence of Various Types of Cancer in 2012
Exhibit 4: FDA Classification of Medical Devices by Type of Class
Exhibit 5: Global Cancer Biomarkers Market by Geographical Segmentation 2014
Exhibit 6: Global Cancer Biomarkers Market by Geographical Segmentation 2019
Exhibit 7: Cancer Biomarkers Market in the Americas 2014-2019 (US$ billion)
Exhibit 8: Cancer Biomarkers Market in US 2014-2019 (US$ billion)
Exhibit 9: Cancer Biomarkers Market in the EMEA Region 2014-2019 (US$ billion)
Exhibit 10: Cancer Biomarkers Market in the APAC Region 2014-2019 (US$ billion)
Exhibit 11: Global Cancer Biomarkers Market by Geographical Segmentation 2014-2019
Exhibit 12: Abbott Laboratories Inc.: Business Segmentation
Exhibit 13: Abbott Laboratories Inc.: Revenue by Business Segmentation 2012
Exhibit 14: Abbott Laboratories Inc.: Revenue by Business Segmentation 2011 and 2012 (US$ million)
Exhibit 15: Abbott Laboratories Inc.: Revenue by Geographical Segmentation 2012
Exhibit 16: Affymetrix Inc.: Business Segmentation 2013
Exhibit 17: Affymetrix Inc.: Business Segmentation by Revenue 2013
Exhibit 18: Affymetrix Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 19: Affymetrix Inc.: Sales by Geography 2013
Exhibit 20: Illumina: Business Segmentation
Exhibit 21: Illumina: Geographical Segmentation by Revenue 2013
Exhibit 22: Qiagen: Product Segmentation by Revenue 2013
Exhibit 23: Qiagen: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 24: Qiagen: Geographical Segmentation by Revenue 2013
Exhibit 25: Global Cancer Biomarkers Market: Business Segmentation by Revenue 2013
Exhibit 26: Global Cancer Biomarkers Market: Business Segmentation by Revenue 2011-2013 (US$ billion)
Exhibit 27: Global Cancer Biomarkers Market: Geographical Segmentation by Revenue 2013
Exhibit 28: Roche Diagnostics: Business Segmentation by Revenue 2013
Exhibit 29: Roche Diagnostics: Geographical Segmentation by Revenue 2013

Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Astellas Pharma US
  • Celldex Therapeutics
  • Exact Sciences
  • Morphotek
  • Polymedco
  • MORE

The author Announces the Publication of its Research Report – Global Cancer Biomarkers Market 2015-2019

The author recognizes the following companies as the key players in the Global Cancer Biomarkers Market: Abbott Laboratories, Affymetrix Inc., Illumina Inc., Qiagen NV, Quest Diagnostics and Roche Diagnostics.

Other Prominent Vendors in the market are: Agendia, Agilent Technologies, Alere, Ambry Genetics, Amgen, Astellas Pharma US, Astex Pharmaceuticals, Atossa Genetics, Beckman Coulter, Becton, Dickinson and Co., Biocurex, bioMérieux, Celldex Therapeutics, Clarient, diaDexus, DiagnoCure, Epigenomics, EUSA Pharma, Exact Sciences, Foundation Medicine, Fujirebio Diagnostics, Genomic Health, Geron, Immunomedics, Morphotek, Myriad Genetics, Nodality, Northwest Biotherapeutics, Ocimum Biosolutions, Oncothyreon, OriGene, Polymedco, Radient Pharmaceuticals, Randox Laboratories, Siemens Healthcare, US Biomarkers and Vermillion.

Commenting on the report, an analyst from the author’s team said: “Growing popularity of companion diagnostics is one of the major trends emerging in this market. Pharmaceutical companies and diagnostic manufacturers are working together to develop such companion diagnostic tests.”

According to the report, the increased prevalence of cancer is one of the key drivers in this market. Globally, the prevalence of cancer is growing at a significant pace. According to researchers, a sedentary lifestyle, poor diet, smoking, and alcohol are among the key external factors contributing to the rise in new cancer cases each year. Some of the internal factors that contribute to the incidence of cancer include inherited mutations, hormonal imbalance, and mutations that occur from metabolism.

Further, the report states that one of the key challenges in the market is the poor regulatory and reimbursement systems. In most countries, regulatory and reimbursement procedures are not ideal to deal with molecular biomarker-based diagnostic tests. Poorly adapted regulatory and reimbursement systems act as a barrier to the inclusion of biomarker-based diagnostic tests in the clinical setting and may further hinder drug development

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Note: Product cover images may vary from those shown
4 of 5

- Abbott Laboratories
- Affymetrix
- Illumina
- Qiagen
- Quest Diagnostics
- Roche Diagnostics
- Agendia
- Agilent Technologies
- Alere
- Ambry Genetics
- Amgen
- Astellas Pharma US
- Astex Pharmaceuticals
- Atossa Genetics
- Beckman Coulter
- Becton
- Dickinson and Company
- Biocurex
- bioMérieux
- Celldex Therapeutics
- Clarient
- diaDexus
- DiagnoCure
- Epigenomics
- EUSA Pharma
- Exact Sciences
- Foundation Medicine
- Fujirebio Diagnostics
- Genomic Health
- Geron
- Immunomedics
- Morphotek
- Myriad Genetics
- Nodality
- NorthwestBiotherapeutics
- Ocimum Biosolutions
- Oncothyreon
- OriGene
- Polymedco
- Radient Pharmaceuticals
- Randox Laboratories
- Siemens Healthcare
- US Biomarkers
- Vermillion

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db